Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Abstract

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published versionRADJENOVIC, A., DALL, B. J., RIDGWAY, J. P. and SMITH, M. A. (2008). Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. British Journal of Radiology, 81 (962), 120-128. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 This paper presents a practical clinical application of a quantitative pharmacokinetic model to study histologically confirmed and graded invasive human breast tumours. The hypothesis was that, given a documented difference in capillary permeability between benign and malignant breast tumours, a relationship between permeability-related DCE-MRI parameters and tumour aggressiveness persists within invasive breast carcinomas. In addition, it was hypothesised that pharmacokinetic parameters may demonstrate stronger correlation with prognostic factors than the more conventional black-box techniques, so a comparison was undertaken. Copyright and re-use policySignificant correlations were found between pharmacokinetic and black-box parameters in 59 invasive breast carcinomas. However, statistically significant variation with tumour grade was only demonstrated in two permeability related pharmacokinetic parameters: k ep (p<0.05) and K trans

Evaluation of the reproducibility of a protocol for the pharmacokinetic study of breast tumors by dynamic magnetic resonance imaging

“…17 However to analyze the importance of this study we need to highlight that the most important constants for the analysis of changes in tumor neovascularization are those that have to do with patency and the passing of contrast through the endothelial membrane (K trans , K ep ). 18 We also performed the segmented analysis of data obtained thanks to one ROI drawn through the tumor perimeter and another ROI including the area of maximum intensity of K trans . It is significant to see how in all cases the concordance of ROI 1 variables is greater than its corresponding ROI 2.…”

A Combined Pharmacokinetic and Radiologic Assessment of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Response to Chemoradiation in Locally Advanced Cervical Cancer

“…Multicompartment models are capable of describing MR contrast uptake using a series of vascular pharmacokinetic parameters (10,11). Although the models used for this type of analysis were originally derived for use in the brain (10), they have been successfully implemented as staging and therapy monitoring tools in a range of cancers (11)(12)(13)(14)(15)(16)(17). More recently, it has been demonstrated that analysis of dynamic contrast-enhanced MRI (DCE-MRI) data using pharmacokinetic models in combination with a routine radiologic assessment of signal intensity curves results in improved diagnostic performance of DCE-MRI classification of breast tumors (18).…”

Heuristic linear mapping of physiological parameters in dynamic contrast‐enhanced MRI without T1 measurement and contrast agent concentration

“…In this case, the use of the proposed linear fitting may lead to fitting deviations. However, according to the reported values in the literature, fortunately very few k ep values over 5/min have been reported for different kinds of tumors and normal tissues (21,(25)(26)(27)(28)(29), indicating the feasibility and practicability of using this mapping method for different DCE-MRI applications. As seen in Table 1, the narrower k ep range to be fit, the better linearity is found between TSF and k ep .…”